Needham & Company Starts Geron Corporation (GERN) at Hold; Six Ongoing Studies, But Outcome Hard to Predict

June 28, 2012 7:43 AM EDT
Get Alerts GERN Hot Sheet
Price: $2.11 --0%

Rating Summary:
    5 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade GERN Now!
Join SI Premium – FREE
Needham & Company initiates coverage on Geron Corporation (NASDAQ: GERN) with a Hold.

Analyst, Chad Messer, said, "Geron has $137 million ($1.06/share) in cash which we are confident is more than required to complete the 6 ongoing studies and devise a registrational path (assuming there is one) for both drugs. However, we do not feel compelled to chase GERN shares without further clinical data and a more defined clinical path for its 2 programs."

For an analyst ratings summary and ratings history on Geron Corporation click here. For more ratings news on Geron Corporation click here.

Shares of Geron Corporation closed at $1.76 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

New Coverage

Related Entities

Needham & Company

Add Your Comment